H.C. Wainwright analyst Ed Arce maintained a Buy rating on Dicerna Pharma (DRNA) today and set a price target of $24. The company’s shares opened today at $14.86.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.4% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Dicerna Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.42.
See today’s analyst top recommended stocks >>
Based on Dicerna Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.02 million. In comparison, last year the company had a GAAP net loss of $15.03 million.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
